File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Mutational status of epidermal growth factor receptor is the only predictor of clinical response to gefitinib treatment in non-small cell lung cancer

TitleMutational status of epidermal growth factor receptor is the only predictor of clinical response to gefitinib treatment in non-small cell lung cancer
Authors
Issue Date2006
PublisherAmerican Association for Cancer Research
Citation
The 97th AACR Annual Meeting, Washington, D.C., 1-5 April 2006. In Cancer Research, 2006, v. 66 n. 8S, p. 1065 Abstract no. 4539 How to Cite?
AbstractThe clinical profile of lung cancer in Hong Kong shows distinct characteristics. The incidences in both genders are comparable to those in Western populations with male (M):female (F) ratio of 2.4:1 in 2002. However, the majority of the women have never smoked and the smoker (SM):non-smoker (NS) ratio was 0.3:1, compared to 6.2:1 in male patients. Consistent with findings in various Asian populations, we have previously shown that mutations of the epidermal growth factor receptor (EGFR) in lung cancers are associated with adenocarcinomas, women and non-smokers. The purpose of this study was to examine the clinical correlates and EGFR mutational status (exons 18 to 21) of non-small cell lung cancer (NSCLC) in relation to clinical responses to the tyrosine kinase inhibitor gefitinib (Iressa). All patients who had resistant disease to conventional chemotherapy, had available clinical material (biopsy, fine needle aspiration, lavage or pleural effusion fluid) for mutation analysis, and who received gefitinib treatment in our institution were retrospectively evaluated. There were 27 F (26 NS, 1 SM) and 16 M (9 NS, 7 SM, p=0.002) aged 35-85 (median 64), and included 32 histologically confirmed adenocarcinomas (AD), 2 squamous and 9 NSCLC of advanced stage disease (IIIB and IV). Gefitinib (250mg/day) was given for 0.5 to 21.2 (median 3) months and patients were monitored for 0.5 to 26.4 (median 6.3) months. The median survival was 10.5 months (95% CI, 8.3-12.7) and one-year survival rate was 37.3%. There were 25 mutations (9 substitutions, 17 deletions) that resulted in amino acid changes from 20 F, 5 M (p=0.010), and 23 NS, 2 SM (p=0.052). One case showed both exon 19 deletion and exon 20 substitution. Common changes (exon 19 deletions, L858R) involved 88% of the mutants. 2 other cases showed silent mutations. Clinical response (CR) from gefitinib treatment was observed in 23 (53.5%) patients who showed either reduction of longest tumour diameter by ≥30%, improvement in performance status, and/or reduced serum carcinoembryonic antigen tumour marker. They included 17/27 (63%) female, 6/16 (37.5%) male, 19/35 (54.3%) NS, 4/8 (50%) SM, and 19/32 (59.4%) AD. Clinical response was correlated only with the EGFR mutation status (19/25 mutants, 4/18 wild types, p<0.001) but not patient gender, smoking history or tumor diagnosis. Survival analysis showed that patients with EGFR mutation had significantly better outcome than those without mutation (one-year survival rate 55.5% vs. 10.6%, p=0.013). Within the limits of the small patient number of this study, the data suggested that the EGFR mutational status is the only predictor of clinical response to gefitinib treatment for NSCLC in our population. (Supported by HKU CRCG 200507176201)
Persistent Identifierhttp://hdl.handle.net/10722/101287
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorWong, MPen_HK
dc.contributor.authorChua, DTTen_HK
dc.contributor.authorHo, JCMen_HK
dc.contributor.authorTam, IYSen_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorChung, LPen_HK
dc.date.accessioned2010-09-25T19:43:30Z-
dc.date.available2010-09-25T19:43:30Z-
dc.date.issued2006en_HK
dc.identifier.citationThe 97th AACR Annual Meeting, Washington, D.C., 1-5 April 2006. In Cancer Research, 2006, v. 66 n. 8S, p. 1065 Abstract no. 4539-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/101287-
dc.description.abstractThe clinical profile of lung cancer in Hong Kong shows distinct characteristics. The incidences in both genders are comparable to those in Western populations with male (M):female (F) ratio of 2.4:1 in 2002. However, the majority of the women have never smoked and the smoker (SM):non-smoker (NS) ratio was 0.3:1, compared to 6.2:1 in male patients. Consistent with findings in various Asian populations, we have previously shown that mutations of the epidermal growth factor receptor (EGFR) in lung cancers are associated with adenocarcinomas, women and non-smokers. The purpose of this study was to examine the clinical correlates and EGFR mutational status (exons 18 to 21) of non-small cell lung cancer (NSCLC) in relation to clinical responses to the tyrosine kinase inhibitor gefitinib (Iressa). All patients who had resistant disease to conventional chemotherapy, had available clinical material (biopsy, fine needle aspiration, lavage or pleural effusion fluid) for mutation analysis, and who received gefitinib treatment in our institution were retrospectively evaluated. There were 27 F (26 NS, 1 SM) and 16 M (9 NS, 7 SM, p=0.002) aged 35-85 (median 64), and included 32 histologically confirmed adenocarcinomas (AD), 2 squamous and 9 NSCLC of advanced stage disease (IIIB and IV). Gefitinib (250mg/day) was given for 0.5 to 21.2 (median 3) months and patients were monitored for 0.5 to 26.4 (median 6.3) months. The median survival was 10.5 months (95% CI, 8.3-12.7) and one-year survival rate was 37.3%. There were 25 mutations (9 substitutions, 17 deletions) that resulted in amino acid changes from 20 F, 5 M (p=0.010), and 23 NS, 2 SM (p=0.052). One case showed both exon 19 deletion and exon 20 substitution. Common changes (exon 19 deletions, L858R) involved 88% of the mutants. 2 other cases showed silent mutations. Clinical response (CR) from gefitinib treatment was observed in 23 (53.5%) patients who showed either reduction of longest tumour diameter by ≥30%, improvement in performance status, and/or reduced serum carcinoembryonic antigen tumour marker. They included 17/27 (63%) female, 6/16 (37.5%) male, 19/35 (54.3%) NS, 4/8 (50%) SM, and 19/32 (59.4%) AD. Clinical response was correlated only with the EGFR mutation status (19/25 mutants, 4/18 wild types, p<0.001) but not patient gender, smoking history or tumor diagnosis. Survival analysis showed that patients with EGFR mutation had significantly better outcome than those without mutation (one-year survival rate 55.5% vs. 10.6%, p=0.013). Within the limits of the small patient number of this study, the data suggested that the EGFR mutational status is the only predictor of clinical response to gefitinib treatment for NSCLC in our population. (Supported by HKU CRCG 200507176201)-
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research-
dc.relation.ispartofCancer Researchen_HK
dc.titleMutational status of epidermal growth factor receptor is the only predictor of clinical response to gefitinib treatment in non-small cell lung canceren_HK
dc.typeConference_Paperen_HK
dc.identifier.emailWong, MP: mwpik@hkucc.hku.hken_HK
dc.identifier.emailChua, DTT: danielchua@hksh.comen_HK
dc.identifier.emailHo, JCM: jhocm@hku.hken_HK
dc.identifier.emailTam, IYS: h9718676@graduate.hku.hken_HK
dc.identifier.emailLam, WK: lamwk@hku.hken_HK
dc.identifier.emailChung, LP: lpchung@hkucc.hku.hken_HK
dc.identifier.authorityWong, MP=rp00348en_HK
dc.identifier.authorityHo, JCM=rp00258en_HK
dc.identifier.authorityChung, LP=rp00249en_HK
dc.identifier.hkuros122174en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats